Results 131 to 140 of about 3,513 (158)

Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data. [PDF]

Headache
Giacon M, Terrazzino S.
europepmc   +1 more source

Reply to Revol et al.: Interpreting fatality-reporting signals in checkpoint immunotherapy. [PDF]

Proc Natl Acad Sci U S A
Sun Z, Deng X, Guo J, Liu M, Chen G, Guan M, Jin H.   +6 more
europepmc   +1 more source

Muscle Atrophy-Related Adverse Events of Antidiabetic Drug Classes: A Pharmacovigilance Analysis Using VigiBase Data. [PDF]

J Cachexia Sarcopenia Muscle
Ueta S, Niimura T, Goda M, Ishida T, Iwata N, Takeda T, Kawada K, Miyata K, Aizawa F, Yagi K, Hamano H, Chuma M, Izawa-Ishizawa Y, Zamami Y, Ishizawa K.   +14 more
europepmc   +1 more source

Hypomagnesemia in patients on oral EGFR tyrosine kinase inhibitors: renal magnesium wasting or concurrent confounders? [PDF]

Clin Kidney J
Ilyas M, Nguyen J, Shettigar S, Rathi K, Kim E, LeClaire J, Mathavan A, Mathavan A, Fares A, Shah CV.   +9 more
europepmc   +1 more source

Renal adverse events in EGFR-TKI treatment: Comprehensive characterization of clinical patterns and molecular underpinnings. [PDF]

Genes Dis
Xiao H, Lin A, Xu W, Shen J, Chen C, Zhang J, Wei T, Luo P.   +7 more
europepmc   +1 more source

Vigi4Eudra-score: Evaluation of the completeness of spontaneous adverse drug reaction reports in EudraVigilance. [PDF]

PLoS One
Christ P, Dubrall D, Lex D, Grüger T, Schmid M, Sachs B.   +5 more
europepmc   +1 more source

Semiparametric Panel Count Model, With Applications to Signal Detection in Post-Market Drug Surveillance Systems. [PDF]

Stat Med
Zhou Y, Yuan A, Tan M.
europepmc   +1 more source

A pharmacovigilance data-driven approach to reveal high fatal adverse events following checkpoint immunotherapy. [PDF]

Proc Natl Acad Sci U S A
Sun Z, Deng X, Guo J, Liu M, Wang S, Wang J, Zheng J, Niu K, Shen W, Ye Z, Zheng C, Wang H, Yang F, Bao Z, Chan KM, Chen G, Guan M, Jin H.   +17 more
europepmc   +1 more source

Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy. [PDF]

Blood Adv
Le Henaff JR, Le Guennec L, Schiro P, Bihan K, Gasnault J, Stankoff B, Taoufik Y, Treiner E, Bensoussan D, Lhomme S, L'Honneur AS, Bonneville F, Shor N, Pourcher V, Pignolet B, Lievin B, Javaux C, Le Guen J, Brissot E, Limouzin PA, Richaud C, Lioure B, Wirth T, Petitgas P, Herbel S, Coustillères F, Rusu EC, Maerten L, Perrot A, Sommet A, Roos-Weil D, Lafaurie M, Weiss N, Martin-Blondel G, THEOREM Study Group.   +34 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A VigiBase Descriptive Study of Fluoroquinolone-Associated Peripheral Nervous System Disorders

Pharmaceuticals, 2022
Cristina Mogosan, Camelia Bucşa, Andréea Farcas   +2 more
exaly